Organovo Logo (2 Color Med-Res-082117).png
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
January 25, 2024 08:05 ET | Organovo, Inc.
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD),...
Organovo Logo (2 Color Med-Res-082117).png
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
January 09, 2024 08:05 ET | Organovo, Inc.
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD),...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023 08:05 ET | Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Organovo Logo (2 Color Med-Res-082117).png
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 13, 2023 08:05 ET | Organovo, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was incorrect. The corrected release follows: ...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 08, 2023 08:05 ET | Organovo, Inc.
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Organovo Logo (2 Color Med-Res-082117).png
Organovo to Participate in the H.C. Wainwright Global Investment Conference
September 08, 2023 12:46 ET | Organovo, Inc.
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
August 23, 2023 08:05 ET | Organovo, Inc.
SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Announces FXR Program
March 21, 2023 08:05 ET | Organovo, Inc.
SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
November 15, 2022 08:05 ET | Organovo, Inc.
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using...
Organovo Logo (2 Color Med-Res-082117).png
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:20 ET | Organovo, Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate...